India launches its first cervical cancer vaccine, Serum likely to keep cost ₹200-4001 min read . Updated: 02 Sep 2022, 01:58 AM IST
- The government said that ‘CERVAVAC’ is an outcome of a partnership of DBT and BIRAC with the Bill and Melinda Gates Foundation, supported by Serum Institute for the indigenous development
NEW DELHI : The Central government launched India first vaccine against cervical cancer--Quadrivalent Human Papillomavirus vaccine (qHPV), has been developed by the Serum Institute of India (SII) and the Department of Biotechnology (DBT) on Thursday. According to the Serum Institute, the vaccine is likely to cost 200-400 per dose.
Select your Category